Navigation Links
MIT radar technology fights breast cancer

CAMBRIDGE, Mass.--Treating breast cancer with a type of heat therapy derived from MIT radar research can significantly increase the effectiveness of chemotherapy, according to results from the fourth clinical trial of the technique reported online Nov. 25 in the journal Cancer Therapy.

In this study, large tumors treated with a combination of chemotherapy and a focused microwave heat treatment shrunk nearly 50 percent more than tumors treated with chemotherapy alone. The microwave treatment is based on technology originally developed at MIT in the late 1980s as a tool for missile detection.

It appears that heating the tumors drastically increased the effectiveness of the chemotherapy, said Dr. William C. Dooley, director of surgical oncology at the University of Oklahoma and the principal investigator of the study. The tumors shrank faster and died faster using the additional microwave hyperthermia on top of the chemotherapy.

According to the National Cancer Institute, some 178,000 women and 2,000 men were diagnosed with breast cancer in 2007. An estimated 40,000 women and 450 men will die of the disease this year.

In the latest clinical trial, fifteen patients received two microwave heat treatments, known as thermotherapy, along with four rounds of chemotherapy before surgery. The goal was to shrink tumors sufficiently to enable a breast-conserving lumpectomy procedure instead of the expected, and more invasive, mastectomy. Surgeons concluded that fourteen of the tumors shrunk enough for this to be possible.

In 1990, Dr. Alan J. Fenn, a senior staff member at MITs Lincoln Laboratory, adapted the thermotherapy treatment from a system that used focused microwaves to detect missiles and block out interfering enemy signals.

Its a very simple idea that can be applied to the treatment of many different cancers, including breast cancer, Fenn said.

The microwaves, delivered by two applicators placed near the breast, kill the cancerous tissue while preserving normal breast tissue by targeting tumor cells that contain high amounts of both water and ions, Fenn explained. When the microwave energy passes through the tumor, the water molecules begin to vibrate and generate heat through friction. This process eventually elevates the cancer cells to a high fever of at least 108 degrees Fahrenheit in most cases, killing them.

The treatment is well tolerated, said Dr. Mary Beth Tomaselli, medical director at Comprehensive Breast Center in Coral Springs, Fla., and a surgeon who was also a co-investigator in the study. The patients who have gone through it had minimal side effects and positive results.

This is the fourth clinical trial of the therapy since 1999. In a Phase-I safety trial using microwave heat alone, researchers found that both small and large breast tumors could be decreased in size between 30 and 60 percent. In a Phase-II dose-escalation trial for small tumors, scientists increased the amount of heat until 100 percent of the tumor cells were killed, prior to the patients receiving a lumpectomy.

Next, researchers treated similar early-stage tumors and noticed that after the surgical removal, none of the patients had tumor cells remaining at the edge of the incision. This is important because additional breast surgery and/or radiation therapy are often recommended for patients that have cancer cells close to the edge of the lumpectomy surgical margin.

The treatment centers for the latest study, which focused on larger tumors, included Harbor-UCLA Medical Center in Torrance, Calif., the University of Oklahoma in Oklahoma City, Comprehensive Breast Center in Coral Springs, Fla., St. Josephs Hospital in Orange, Calif., and five additional sites. Celsion (Canada) Limited licenses the focused microwave thermotherapy technology from MIT, and has produced 10 clinical systems to date to perform the procedures.

The team has applied for approval for a large-scale clinical trial from Health Canada (the equivalent of the US FDA) and will be applying for the same approval from the FDA. Researchers will then test the treatment in a randomized study of 228 patients who have large breast-cancer tumors. Patients will receive either chemotherapy alone or chemotherapy plus microwave heat treatments at one of six participating medical centers in the United States and Canada.

The patients who have the best results in cancer treatment, at least with breast cancer, are patients who have a sequence of different therapies, including chemotherapy, surgery, radiation, and hormones, said Dr. Hernan I. Vargas, associate professor of surgery at UCLA and lead author of the recent study. Each one of the treatments adds a little bit. The thermotherapy might be one more tool that helps us fight this disease.


Contact: Elizabeth Thomson
Massachusetts Institute of Technology

Related medicine news :

1. Quantum light beams good for fast technology
2. New Smart Technology Makes Patient Data Collection Easier, More Efficient
3. Align Technology Executive to Present at Upcoming Financial Conferences
4. Pioneer Surgical Technology Hires Vice President of New Business Development
5. Purdue researchers develop technology to detect cancer by scanning surface veins
6. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
7. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
8. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
9. Stevens Health, Technology and Society roundtable: Sept. 19
10. Microbiotic technology developed for microinjection of zebrafish embryos
11. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... Califia Farms ... announced that its iconic bottle has won top honors in Beverage World Magazine’s Global ... Company also announced that it has been selected as a 2015 U.S.A. Taste Champion ...
(Date:12/1/2015)... MD (PRWEB) , ... December 01, 2015 , ... ... salmon identification tests to continue the expansion of the company’s growing product line ... – for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to ...
(Date:12/1/2015)... ... December 01, 2015 , ... The ... been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s first portable ... Meeting from November 29 to December 4, 2015. , MED-TAB is expected ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... is everything. That is why Hollister Incorporated has launched the VaPro Plus Pocket™ ... next product in the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... today announced it has been awarded a fixed price per sprint agile development ... contract, valued at $34 million over five years, provides software engineering, infrastructure, as ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... 1, 2015 --> ... Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, ... and Pipeline Analysis - Global Forecast to 2020", published by ... USD 73,529.2 Million by 2020 from USD 40,281.6 Million in ... Browse 37 market data ...
(Date:12/1/2015)... BANGALORE, India and PITTSBURGH ... TASE: MYL) today announced that it expects to be ... developing country markets funded by international donors, TLE400 (Tenofovir ... Efavirenz 400 mg) for $99 per patient, per year. ... to develop TLE400. The significantly reduced price could generate ...
(Date:12/1/2015)... , Dec. 1, 2015  AccuTEC Blades, a ... new corporate logo and brand identity program. The ... and engineering of bladed products where "the edge ... --> Serving manufacturers and distributors ... auto glass equipment, AccuTEC,s product lines include those ...
Breaking Medicine Technology: